Identification of sites of degradation in a therapeutic monoclonal antibody by peptide mapping
- PMID: 1475223
- DOI: 10.1023/a:1015894409623
Identification of sites of degradation in a therapeutic monoclonal antibody by peptide mapping
Abstract
A peptide mapping procedure was developed to locate regions of a monoclonal antibody, OKT3, that undergo chemical modification as the molecule degrades upon storage. The structures of these peptide degradation products were investigated. Deamidation at specific asparagine residues and oxidation of a cysteine and several methionines were found to be major routes of OKT3 degradation. A unique chain cross-linked degradation product was also observed and characterized. Changing the storage conditions of the antibody affected the relative distribution of degradation products. These results were useful in the development of more stable formulations for OKT3, and the methods can be used in the characterization of other monoclonal antibodies intended for therapeutic use.
Similar articles
-
Orthoclone OKT3. Chemical mechanisms and functional effects of degradation of a therapeutic monoclonal antibody.Pharm Biotechnol. 1993;5:135-58. Pharm Biotechnol. 1993. PMID: 8019692 Review. No abstract available.
-
Identification and characterization of oxidation and deamidation sites in monoclonal rat/mouse hybrid antibodies.J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Mar 15;878(9-10):777-84. doi: 10.1016/j.jchromb.2010.01.036. Epub 2010 Jan 29. J Chromatogr B Analyt Technol Biomed Life Sci. 2010. PMID: 20153988
-
Effect of a single amino acid mutation on the activating and immunosuppressive properties of a "humanized" OKT3 monoclonal antibody.J Immunol. 1992 Jun 1;148(11):3461-8. J Immunol. 1992. PMID: 1534096
-
Characterization of asparagine 330 deamidation in an Fc-fragment of IgG1 using cation exchange chromatography and peptide mapping.J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Aug 15;965:65-71. doi: 10.1016/j.jchromb.2014.06.018. Epub 2014 Jun 21. J Chromatogr B Analyt Technol Biomed Life Sci. 2014. PMID: 24999246
-
Oxidation and Deamidation of Monoclonal Antibody Products: Potential Impact on Stability, Biological Activity, and Efficacy.J Pharm Sci. 2022 Apr;111(4):903-918. doi: 10.1016/j.xphs.2021.11.024. Epub 2021 Dec 7. J Pharm Sci. 2022. PMID: 34890632 Review.
Cited by
-
Simultaneous assessment of Asp isomerization and Asn deamidation in recombinant antibodies by LC-MS following incubation at elevated temperatures.PLoS One. 2012;7(1):e30295. doi: 10.1371/journal.pone.0030295. Epub 2012 Jan 17. PLoS One. 2012. PMID: 22272329 Free PMC article.
-
Biological Insights into Therapeutic Protein Modifications throughout Trafficking and Their Biopharmaceutical Applications.Int J Cell Biol. 2013;2013:273086. doi: 10.1155/2013/273086. Epub 2013 Apr 18. Int J Cell Biol. 2013. PMID: 23690780 Free PMC article.
-
Developability considerations for bispecific and multispecific antibodies.MAbs. 2024 Jan-Dec;16(1):2394229. doi: 10.1080/19420862.2024.2394229. Epub 2024 Aug 27. MAbs. 2024. PMID: 39189686 Free PMC article. Review.
-
Structural and biochemical basis of the formation of isoaspartate in the complementarity-determining region of antibody 64M-5 Fab.Sci Rep. 2019 Dec 6;9(1):18494. doi: 10.1038/s41598-019-54918-0. Sci Rep. 2019. PMID: 31811216 Free PMC article.
-
Analytical comparability study of recombinant monoclonal antibody therapeutics.MAbs. 2018 May/Jun;10(4):513-538. doi: 10.1080/19420862.2018.1438797. Epub 2018 Mar 20. MAbs. 2018. PMID: 29513619 Free PMC article. Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources